Dubbed "the new blockbuster" by Bayer AG management, the PDE5 inhibitor vardenafil is by most accounts more potent, faster acting, and less prone to side effects than its pharmaceutical cousin, Pfizer Inc. 's sildenafil (Viagra). Solid clinical results and a savvy marketing effort could expand the market for erectile dysfunction treatment and snap up audience share from the Pfizer juggernaut.
But vardenafil's potential—and its role as a potential savior of Bayer's ailing pharmaceuticals division—may be overshadowed by the chinks that...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?